VKTX vs. ROIV, ASND, LEGN, CERE, CTLT, JAZZ, ITCI, UTHR, ELAN, and CYTK
Should you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Intra-Cellular Therapies (ITCI), United Therapeutics (UTHR), Elanco Animal Health (ELAN), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical preparations" industry.
Roivant Sciences (NASDAQ:ROIV) and Viking Therapeutics (NASDAQ:VKTX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, community ranking, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.
Viking Therapeutics has lower revenue, but higher earnings than Roivant Sciences. Viking Therapeutics is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
Roivant Sciences presently has a consensus target price of $16.90, indicating a potential upside of 50.76%. Viking Therapeutics has a consensus target price of $112.25, indicating a potential upside of 40.47%. Given Viking Therapeutics' higher probable upside, equities analysts clearly believe Roivant Sciences is more favorable than Viking Therapeutics.
In the previous week, Viking Therapeutics had 15 more articles in the media than Roivant Sciences. MarketBeat recorded 16 mentions for Viking Therapeutics and 1 mentions for Roivant Sciences. Viking Therapeutics' average media sentiment score of 1.00 beat Roivant Sciences' score of 0.62 indicating that Roivant Sciences is being referred to more favorably in the media.
Roivant Sciences has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.
Viking Therapeutics received 555 more outperform votes than Roivant Sciences when rated by MarketBeat users. Likewise, 79.92% of users gave Viking Therapeutics an outperform vote while only 75.00% of users gave Roivant Sciences an outperform vote.
64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 4.6% of Roivant Sciences shares are held by insiders. Comparatively, 4.7% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Roivant Sciences has a net margin of 3,624.14% compared to Roivant Sciences' net margin of 0.00%. Roivant Sciences' return on equity of -18.41% beat Viking Therapeutics' return on equity.
Summary
Viking Therapeutics beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.
Get Viking Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viking Therapeutics Competitors List
Related Companies and Tools
